Wellpath LLC

Wellpath LLC, doing business as Recovery Solutions, a Nashville, Tennessee-based for-profit limited liability company, provides comprehensive healthcare services to federal correctional facilities as a prime contractor, competing without set-aside protections in full-and-open competition. The vendor operates 100% as a prime (3,023 awards) across the Federal Bureau of Prisons system and related federal detention agencies, with minimal sub-award footprint (2 sub-awards accounting for less than 1% of activity). Wellpath is a large business with no designated ownership certifications.

Wellpath's federal footprint centers almost entirely on correctional healthcare delivery — medical, dental, behavioral health, pharmacy, and telehealth services to incarcerated populations. The portfolio spans 3,025 federal awards since 2012, with a combined potential value of $1.12 billion and $612.7 million in obligated dollars (55% drawn). Activity has remained relatively stable over the past five years (194–269 awards annually; 202 awards in 2026 year-to-date), with the most recent award on September 1, 2026. The portfolio is organized around monthly and periodic delivery orders and purchase orders placed against multiple IDV vehicles, with individual award values typically ranging from $80 to $2.4 million.

Customer concentration is extreme and non-diversifiable. The top five Bureau of Prisons facilities account for 52% of award count (1,566 awards) and 64% of combined potential value ($718.3 million). Federal Correctional Complex Coleman dominates both metrics — 427 awards worth $334.9 million combined potential value. Federal Correctional Complex Beaumont, Federal Correctional Institution Terminal Island, Federal Correctional Complex Victorville, and Federal Correctional Institution El Reno round out the top five by potential value. All 30 named customer agencies are BOP facilities or BOP-affiliated detention centers; no other federal agency appears in the customer base. This concentration creates substantial recompete risk: 60 awards (combined potential value $25.3 million) reach ultimate completion within the next twenty-four months.

Wellpath's IDV posture anchors on three primary vehicles. The $39.98 million single-award Medication-Assisted Treatment (MAT) contract (awarded October 1, 2024, completion September 30, 2027) carries 256 task orders worth $156 million combined potential value and establishes the framework for nationwide MAT intake screening, psychiatric evaluation, follow-up care, medication administration, and reporting across federal correctional custody and community supervision settings. Two supplementary telehealth-focused MAT contracts (September 1, 2024; completion September 30, 2024 and August 30, 2024 respectively) totaling approximately $1.75 million provide buprenorphine and naltrexone follow-up and psychiatric evaluations for offenders in residential reentry centers, home confinement, and federal location monitoring. Against these and other IDVs, Wellpath executes hundreds of monthly firm-fixed-price delivery orders and purchase orders across multiple facilities, reflecting the Bureau's systematic reliance on the vendor's healthcare infrastructure.

Wellpath holds a subsidiary, Conmed, Inc., named in the corporate structure block. Award history does not clarify the subsidiary's distinct role or capability contribution.

Federal grant engagement is minimal. A single telemedicine project grant from the Department of Agriculture Rural Utilities Service (award date February 1, 2024; completion February 1, 2026) carries a small dollar value and does not represent material diversification beyond correctional contract work. No sub-grant or sub-recipient awards appear in the source.

Wellpath's NAICS concentration is absolute: 2,988 of 3,025 awards (98.8%) fall under General Medical and Surgical Hospitals (NAICS 622110), with 15 awards in Offices of Physicians and 13 in Outpatient Mental Health and Substance Abuse Centers rounding out the remainder. PSC coding reinforces this: 2,021 awards carry Medical-Managed Healthcare (R405), 957 carry Medical-Other (R499), and 11 carry Medical-Optometry (R405A). This vendor has no diversification outside correctional healthcare and no presence across civilian VA, DoD, or civilian health agency programs.

The absence of meaningful sub-award activity and the uniform monthly delivery-order structure mean Wellpath operates as a direct healthcare provider to individual facilities rather than a system integrator or teaming prime. No named subcontractors or teaming relationships surface in the award data provided. The sub-award listed under the portfolio (Science Applications International Corporation on a FAA systems engineering contract, January 30, 2024) is non-representative of Wellpath's primary business and likely reflects legacy or outlier activity.

Wellpath competes entirely in full-and-open, unrestricted federal procurement. No set-aside awards (8(a), HUBZone, SDVOSB, WOSB) appear across the 3,025-award portfolio; all awards explicitly carry "No Set-Aside Used" designations and name Wellpath as a "large business" when business-size language is present. This posture reflects the company's choice to compete against all eligible contractors rather than leverage small-business certification, consistent with a well-capitalized, integrated healthcare provider to the federal corrections system.